(Q24202443)

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Immunoglobulin treatment in refractory Myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Manipulating the Immune System with Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Plasma exchange for myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Plasmapheresis in refractory generalized myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Long-term effects of repeated plasma exchange in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Remission of myasthenia gravis following plasma-exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Intravenous immunoglobulin for myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002277.PUB4

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

21 January 2018

1 reference

12 December 2020

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity

1 reference

12 December 2020

Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins

1 reference

12 December 2020

Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients

1 reference

12 December 2020

Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients

1 reference

12 December 2020

Experience with intravenous immunoglobulin in myasthenia gravis

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

12 December 2020

Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis

1 reference

12 December 2020

High-dose intravenous immunoglobulin in the management of myasthenia gravis

1 reference

12 December 2020

Long-term effects of plasma exchange in myasthenia. Results of a randomized study

1 reference

12 December 2020

Treatment of myasthenia gravis with high-dose intravenous immunoglobulin

1 reference

12 December 2020

NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease

1 reference

12 December 2020

Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome

1 reference

12 December 2020

High-dose intravenous gammaglobulin for myasthenia gravis

1 reference

12 December 2020

A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia

1 reference

12 December 2020

The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Development

1 reference

12 December 2020

Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin

1 reference

12 December 2020

Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis

1 reference

12 December 2020

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

1 reference

12 December 2020

Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin.

1 reference

12 December 2020

Chronic long-interval plasma exchange in myasthenia gravis

1 reference

12 December 2020